JP2003516151A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516151A5
JP2003516151A5 JP2001544332A JP2001544332A JP2003516151A5 JP 2003516151 A5 JP2003516151 A5 JP 2003516151A5 JP 2001544332 A JP2001544332 A JP 2001544332A JP 2001544332 A JP2001544332 A JP 2001544332A JP 2003516151 A5 JP2003516151 A5 JP 2003516151A5
Authority
JP
Japan
Prior art keywords
composition
compound
uncharged
bond
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001544332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/042391 external-priority patent/WO2001042457A2/en
Publication of JP2003516151A publication Critical patent/JP2003516151A/ja
Publication of JP2003516151A5 publication Critical patent/JP2003516151A5/ja
Pending legal-status Critical Current

Links

JP2001544332A 1999-11-29 2000-11-29 細菌16Sおよび23SrRNAに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用 Pending JP2003516151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16815099P 1999-11-29 1999-11-29
US60/168,150 1999-11-29
PCT/US2000/042391 WO2001042457A2 (en) 1999-11-29 2000-11-29 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses

Publications (2)

Publication Number Publication Date
JP2003516151A JP2003516151A (ja) 2003-05-13
JP2003516151A5 true JP2003516151A5 (OSRAM) 2008-01-17

Family

ID=22610334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001544332A Pending JP2003516151A (ja) 1999-11-29 2000-11-29 細菌16Sおよび23SrRNAに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用

Country Status (9)

Country Link
US (2) US6677153B2 (OSRAM)
EP (1) EP1238071B1 (OSRAM)
JP (1) JP2003516151A (OSRAM)
KR (1) KR20020064915A (OSRAM)
AT (1) ATE393221T1 (OSRAM)
AU (1) AU783874B2 (OSRAM)
CA (1) CA2392685C (OSRAM)
DE (1) DE60038695T2 (OSRAM)
WO (1) WO2001042457A2 (OSRAM)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042457A2 (en) * 1999-11-29 2001-06-14 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
RU2329305C2 (ru) * 2001-03-01 2008-07-20 Дзе Джонс Хопкинс Юниверсити Количественный анализ, позволяющий одновременно обнаруживать и идентифицировать бактериальные инфекции
US7326779B2 (en) * 2001-10-15 2008-02-05 Nissin Food Products Co., Ltd. Primers and method of detecting bacteria
GB0126415D0 (en) * 2001-11-02 2002-01-02 Univ Warwick Enzymes and enzyme inhibition
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
WO2005000193A2 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1583713B1 (en) * 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
JP2004313181A (ja) * 2003-04-02 2004-11-11 Canon Inc 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US7750142B2 (en) * 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
EP1629105B1 (en) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
AU2004263124B2 (en) * 2003-08-07 2009-01-15 Avi Biopharma, Inc. Sense antiviral compound and method for treating ssRNA viral infection
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
CA2540407A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
US8007847B2 (en) * 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US20050234002A1 (en) 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
ATE510914T1 (de) 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US8129352B2 (en) * 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
US7300631B2 (en) * 2005-05-02 2007-11-27 Bioscale, Inc. Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles
US20060293268A1 (en) * 2005-05-05 2006-12-28 Rieder Aida E Antisense antiviral compounds and methods for treating foot and mouth disease
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US20060292575A1 (en) * 2005-06-24 2006-12-28 Asiagen Corporation Novel method for diagnosing pathogens of sexually transmitted diseases
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
EP1937278B1 (en) * 2005-09-08 2012-07-25 AVI BioPharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
JP4827483B2 (ja) * 2005-10-04 2011-11-30 キヤノン株式会社 核酸試料処理装置
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US7582615B2 (en) * 2006-03-07 2009-09-01 Avi Biopharma, Inc. Antisense antiviral compound and method for treating arenavirus infection
WO2007123386A1 (es) * 2006-04-24 2007-11-01 Sigma Alimentos, S.A. De C.V. Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real
HUE035799T2 (en) * 2006-05-10 2018-05-28 Sarepta Therapeutics Inc Cationic oligonucleotide analogues containing subunits
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20070265215A1 (en) * 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
US7598040B2 (en) 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
US20090035767A1 (en) * 2006-11-28 2009-02-05 Canon Kabushiki Kaisha Primer for bacterium genome amplification reaction
US20080173652A1 (en) * 2007-01-23 2008-07-24 Bob Chou Integral heat-resisting structure of a disposable drinking cup
CA2691066C (en) 2007-02-09 2018-07-31 Northwestern University Particles for detecting intracellular targets
DK2160464T3 (da) * 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
AU2008301890A1 (en) * 2007-09-14 2009-03-26 North Carolina State University Compositions and methods for the identification of inhibitors of retroviral infection
CN102112625B (zh) * 2008-03-03 2013-11-20 学校法人埼玉医科大学 造成急性呼吸道感染的炎性病原体的鉴别方法
KR100966015B1 (ko) * 2008-03-24 2010-06-24 이화여자대학교 산학협력단 식중독 병원균의 동시 검출용 프라이머 및 이의 용도
CA2776044A1 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
CN102281872A (zh) 2008-11-24 2011-12-14 西北大学 多价rna纳米颗粒组合物
AU2009335740B2 (en) * 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20100233270A1 (en) * 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
MX2011007350A (es) * 2009-01-08 2011-09-06 Univ Northwestern Inhibicion de produccion de proteina bacteriana por conjugados de nanoparticulas modificadas por oligonucleotidos polivalentes.
JP6145270B2 (ja) 2009-04-15 2017-06-07 ノースウェスタン ユニバーシティ オリゴヌクレオチド機能化ナノ粒子の送達
EP2446057B1 (en) 2009-06-23 2014-11-19 Gen-Probe Incorporated Compositions and methods for detecting nucleic acid from mollicutes
WO2011019993A2 (en) 2009-08-14 2011-02-17 Epicentre Technologies Corporation METHODS, COMPOSITIONS, AND KITS FOR GENERATING rRNA-DEPLETED SAMPLES OR ISOLATING rRNA FROM SAMPLES
AU2010313154B2 (en) 2009-10-30 2016-05-12 Northwestern University Templated nanoconjugates
CA2779830C (en) 2009-11-13 2020-07-21 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP2525780B1 (en) 2010-01-19 2022-09-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
CN107353317A (zh) 2010-05-28 2017-11-17 萨勒普塔医疗公司 具有修饰的亚基间键和/或端基的寡核苷酸类似物
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
EP2638161A1 (en) * 2010-11-12 2013-09-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
WO2012066549A1 (en) 2010-11-15 2012-05-24 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
CA2847698C (en) 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
DK2758533T3 (en) 2011-09-20 2018-05-28 Ionis Pharmaceuticals Inc ANTISENCE MODULATION OF GCGR EXPRESSION
WO2013043777A1 (en) * 2011-09-21 2013-03-28 Syngenta Participations Ag Pathogen resistance
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス, インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
EP2812434B1 (en) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
WO2014073560A1 (ja) * 2012-11-09 2014-05-15 株式会社村田製作所 二次電池、及び二次電池の充放電方法
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
US11359249B2 (en) * 2014-05-06 2022-06-14 Is-Diagnostics Ltd Microbial population analysis
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
JP6797108B2 (ja) 2014-08-19 2020-12-09 ノースウェスタン ユニバーシティ タンパク質/オリゴヌクレオチドコアシェルナノ粒子治療薬
KR20170063949A (ko) 2014-10-06 2017-06-08 엑시큐어, 인크. 항-tnf 화합물
WO2016061398A1 (en) * 2014-10-17 2016-04-21 Fred Hutchinson Cancer Research Center Methods, kits & compositions to assess helicobacter pylori infection
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA3009342A1 (en) * 2015-12-23 2017-06-29 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US10968489B2 (en) 2016-05-10 2021-04-06 American Molecular Laboratories Inc. Methods and compositions for characterizing drug resistant bacteria from formalin-fixed paraffin-embedded biological samples
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
WO2019032572A1 (en) * 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES
EP3728601A4 (en) * 2018-01-17 2021-03-17 Augmanity Nano Ltd ANTI-PATHOGENIC NUCLEIC ACID SET, THEIR COMPOSITIONS AND USES
EP3952645A4 (en) * 2019-04-08 2023-08-23 University Of Massachusetts Localization of payload delivery systems to tumor sites via beacon cell targeting
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220014A (en) * 1989-11-13 1993-06-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rrna specific oligonucleotides
CA2069869C (en) * 1989-12-20 1995-12-19 James E. Summerton Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5821052A (en) 1992-04-16 1998-10-13 University Of Medicine And Dentistry Of New Jersey Control of the synthesis of proteins by anitisense RNA-tRNA complex
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
GB9505438D0 (en) 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
AU3811897A (en) * 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
AU742521B2 (en) * 1997-01-24 2002-01-03 Avi Biopharma, Inc. Method and conjugate for treating H. pylori infection
EP0975370B9 (en) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6204019B1 (en) 1997-06-04 2001-03-20 Smithkline Beecham Corporation Sec A2 from Streptococcus pneumoniae
US6610539B1 (en) 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP0894857A3 (en) 1997-08-01 2001-09-26 Smithkline Beecham Corporation SecA gene from Streptococcus pneumoniae
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6228579B1 (en) 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
WO2001042457A2 (en) 1999-11-29 2001-06-14 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses
US7049431B2 (en) 2000-01-04 2006-05-23 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method

Similar Documents

Publication Publication Date Title
JP2003516151A5 (OSRAM)
CA2392685A1 (en) Antisense antibacterial method and composition
JP5801205B2 (ja) 多価オリゴヌクレオチド修飾ナノ粒子コンジュゲートによる細菌タンパク質産生の阻害
US7049431B2 (en) Antisense antibacterial cell division composition and method
CN115697420A (zh) 一种治疗赫勒氏综合征的方法和药物
ES2367289T3 (es) Método y compuesto antibacteriano antisentido.
US20160251398A1 (en) Antibacterial antisense oligonucleotide and method
US7790694B2 (en) Antisense antibacterial method and compound
CA2614191C (en) Antisense antibacterial method and compound
CN108350454A (zh) 等位基因选择性基因编辑及其用途
JP2003518946A5 (OSRAM)
JP2004509619A5 (OSRAM)
JP7770769B2 (ja) 免疫刺激性オリゴヌクレオチド
CA2358570C (en) Protonated/acidified nucleic acids and methods of use
JP2010526541A5 (OSRAM)
JP2024112834A5 (OSRAM)
JP2005504522A5 (OSRAM)
JP2019500902A5 (OSRAM)
Versalovic et al. Interspersed repetitive sequences in bacterial genomes
WO2000015265A1 (en) Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
US6136602A (en) Oligonucleotides specific for the marORAB operon
JP2007501621A5 (OSRAM)
Szczepanowski et al. Different molecular rearrangements in the integron of the IncP-1β resistance plasmid pB10 isolated from a wastewater treatment plant result in elevated β-lactam resistance levels
RU2024106447A (ru) Антисмысловые олигонуклеотиды, нацеленные на ген cav3.1, и их применения
EP1220903A1 (en) Gene selection using pnas